| 000 | 01509 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513112918.0 | ||
| 264 | 0 | _c19970529 | |
| 008 | 199705s 0 0 eng d | ||
| 022 | _a0306-5251 | ||
| 024 | 7 |
_a10.1111/j.1365-2125.1997.tb00032.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSciberras, D G | |
| 245 | 0 | 0 |
_aInitial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist. _h[electronic resource] |
| 260 |
_bBritish journal of clinical pharmacology _cJan 1997 |
||
| 300 |
_a49-54 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAnalysis of Variance |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aHeart Rate _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMigraine Disorders _xmetabolism |
| 650 | 0 | 4 |
_aSerotonin Receptor Agonists _xadverse effects |
| 650 | 0 | 4 |
_aSumatriptan _xpharmacokinetics |
| 650 | 0 | 4 |
_aTriazoles _xadverse effects |
| 650 | 0 | 4 | _aTryptamines |
| 700 | 1 | _aPolvino, W J | |
| 700 | 1 | _aGertz, B J | |
| 700 | 1 | _aCheng, H | |
| 700 | 1 | _aStepanavage, M | |
| 700 | 1 | _aWittreich, J | |
| 700 | 1 | _aOlah, T | |
| 700 | 1 | _aEdwards, M | |
| 700 | 1 | _aMant, T | |
| 773 | 0 |
_tBritish journal of clinical pharmacology _gvol. 43 _gno. 1 _gp. 49-54 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2125.1997.tb00032.x _zAvailable from publisher's website |
| 999 |
_c9044174 _d9044174 |
||